Medtronic (NYSE: MDT) reported Q2 EPS of $1.03, $0.03 better than the analyst estimate of $1.00. Revenue for the quarter came in at $7.1 million versus the consensus estimate of $7.06 million.

GUIDANCE:

Medtronic sees FY16 EPS of $4.33-$4.40, versus prior guidance of $4.30-$4.40 and the consensus of $4.36.

For earnings history and earnings-related data on Medtronic (MDT) click here.